STOCK TITAN

Vaccinex, Inc. - $VCNX STOCK NEWS

Welcome to our dedicated page for Vaccinex news (Ticker: $VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vaccinex's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vaccinex's position in the market.

Rhea-AI Summary
Vaccinex, Inc. announces securities purchase agreements for the sale of 9.6M shares of common stock and warrants, expected to raise $9.6M in gross proceeds. The funds will be used for the development of its lead drug candidate and other corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.17%
Tags
-
Rhea-AI Summary
Vaccinex announces a new publication in the journal mAbs describing a novel way in which its proprietary ActivMAb® poxvirus platform can enable the presentation of high complexity, hard-to-drug proteins as targets for antibody discovery. The application was successfully used with OmniAb's platform to select antibodies against challenging multipass membrane targets. This new application is a powerful complement to Vaccinex's ActivMAb platform and can accelerate the development of novel therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.82%
Tags
none
-
Rhea-AI Summary
Vaccinex to present update on Phase 1b/2 pepinemab/PDAC study and new ActivMAb® application
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
conferences
Rhea-AI Summary
Vaccinex, Inc. will report on novel findings for its lead product, pepinemab, at upcoming medical conferences. Results from the phase 2 SIGNAL trial suggest pepinemab has the potential to prevent decline in brain metabolic activity and slow cognitive decline in Huntington's disease. In combination with a checkpoint inhibitor, pepinemab has shown the potential to induce formation of lymphoid structures in tumors, leading to improved outcomes in head and neck cancer. The company believes pepinemab may be an attractive alternative or combination therapy for Alzheimer's disease. The Phase 2 KEYNOTE-B84 study demonstrated improved objective response rates and progression-free survival in head and neck squamous cell carcinoma patients treated with pepinemab and KEYTRUDA. Treatment with pepinemab in combination with KEYTRUDA also appeared to induce formation of highly organized lymphoid structures in tumors, which correlated with disease control and progression-free survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.64%
Tags
none
-
Rhea-AI Summary
Vaccinex, Inc. announces a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Vaccinex, Inc. announced financial results for Q2 2023 and provided updates on clinical milestones. The Phase 1b/2 SIGNAL-AD trial of pepinemab in Alzheimer's disease achieved full accrual and is expected to complete 12-months treatment in June 2024. Interim results from the Phase 2 KEYNOTE-B84 trial in head and neck cancer showed promising outcomes. Vaccinex is also initiating clinical studies in metastatic pancreatic cancer and breast cancer. The company's cash and cash equivalents were $1.9 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
Vaccinex, Inc.

Nasdaq:VCNX

VCNX Rankings

VCNX Stock Data

8.56M
591.10k
6.76%
41.7%
0.44%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
ROCHESTER

About VCNX

located in rochester, ny, vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. we conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. we are committed to innovation in the way we approach drug discovery and develop